Cargando…

Targeting TGF-β Signaling in Kidney Fibrosis

Renal fibrosis is the final common pathway of numerous progressive kidney diseases, and transforming growth factor-β (TGF-β) has an important role in tissue fibrosis by up-regulating matrix protein synthesis, inhibiting matrix degradation, and altering cell-cell interaction. Many strategies targetin...

Descripción completa

Detalles Bibliográficos
Autor principal: Isaka, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165001/
https://www.ncbi.nlm.nih.gov/pubmed/30150520
http://dx.doi.org/10.3390/ijms19092532
_version_ 1783359733880586240
author Isaka, Yoshitaka
author_facet Isaka, Yoshitaka
author_sort Isaka, Yoshitaka
collection PubMed
description Renal fibrosis is the final common pathway of numerous progressive kidney diseases, and transforming growth factor-β (TGF-β) has an important role in tissue fibrosis by up-regulating matrix protein synthesis, inhibiting matrix degradation, and altering cell-cell interaction. Many strategies targeting TGF-β, including inhibition of production, activation, binding to the receptor, and intracellular signaling, have been developed. Some of them were examined in clinical studies against kidney fibrosis, and some are applied to other fibrotic diseases or cancer. Here, I review the approaches targeting TGF-β signaling in kidney fibrosis.
format Online
Article
Text
id pubmed-6165001
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61650012018-10-10 Targeting TGF-β Signaling in Kidney Fibrosis Isaka, Yoshitaka Int J Mol Sci Review Renal fibrosis is the final common pathway of numerous progressive kidney diseases, and transforming growth factor-β (TGF-β) has an important role in tissue fibrosis by up-regulating matrix protein synthesis, inhibiting matrix degradation, and altering cell-cell interaction. Many strategies targeting TGF-β, including inhibition of production, activation, binding to the receptor, and intracellular signaling, have been developed. Some of them were examined in clinical studies against kidney fibrosis, and some are applied to other fibrotic diseases or cancer. Here, I review the approaches targeting TGF-β signaling in kidney fibrosis. MDPI 2018-08-27 /pmc/articles/PMC6165001/ /pubmed/30150520 http://dx.doi.org/10.3390/ijms19092532 Text en © 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Isaka, Yoshitaka
Targeting TGF-β Signaling in Kidney Fibrosis
title Targeting TGF-β Signaling in Kidney Fibrosis
title_full Targeting TGF-β Signaling in Kidney Fibrosis
title_fullStr Targeting TGF-β Signaling in Kidney Fibrosis
title_full_unstemmed Targeting TGF-β Signaling in Kidney Fibrosis
title_short Targeting TGF-β Signaling in Kidney Fibrosis
title_sort targeting tgf-β signaling in kidney fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165001/
https://www.ncbi.nlm.nih.gov/pubmed/30150520
http://dx.doi.org/10.3390/ijms19092532
work_keys_str_mv AT isakayoshitaka targetingtgfbsignalinginkidneyfibrosis